Royal Bank Of Canada Cuts Incyte (NASDAQ:INCY) Price Target to $92.00

Incyte (NASDAQ:INCY) had its price objective cut by Royal Bank Of Canada from $95.00 to $92.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have a sector perform rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on the company. Stifel Nicolaus increased their price target on Incyte from $119.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday. Piper Sandler boosted their price objective on shares of Incyte from $102.00 to $110.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Barclays boosted their price target on Incyte from $115.00 to $116.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. Wall Street Zen raised Incyte from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Finally, Zacks Research downgraded Incyte from a “strong-buy” rating to a “hold” rating in a report on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $103.94.

Incyte Price Performance

Shares of INCY stock opened at $101.10 on Wednesday. The firm’s 50 day moving average is $101.73 and its 200-day moving average is $94.07. Incyte has a 1 year low of $53.56 and a 1 year high of $112.29. The company has a current ratio of 3.32, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $20.12 billion, a price-to-earnings ratio of 15.77, a PEG ratio of 0.60 and a beta of 0.82.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). Incyte had a net margin of 25.03% and a return on equity of 26.34%. The firm had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.35 billion. During the same quarter in the previous year, the business posted $1.43 earnings per share. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. Sell-side analysts forecast that Incyte will post 4.86 EPS for the current fiscal year.

Insider Activity

In related news, insider Thomas Tray sold 2,774 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $100.00, for a total value of $277,400.00. Following the completion of the sale, the insider directly owned 22,973 shares in the company, valued at approximately $2,297,300. This trade represents a 10.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Mohamed Khairie Issa sold 10,856 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total value of $1,184,063.92. Following the transaction, the executive vice president directly owned 66,132 shares in the company, valued at approximately $7,213,017.24. This trade represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 95,225 shares of company stock worth $9,519,745. Insiders own 17.80% of the company’s stock.

Institutional Trading of Incyte

A number of hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC raised its stake in Incyte by 369.3% in the 1st quarter. NewEdge Advisors LLC now owns 12,597 shares of the biopharmaceutical company’s stock valued at $763,000 after acquiring an additional 9,913 shares during the period. Jones Financial Companies Lllp boosted its position in Incyte by 15.1% during the first quarter. Jones Financial Companies Lllp now owns 4,944 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 648 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Incyte by 6.4% in the first quarter. Goldman Sachs Group Inc. now owns 814,559 shares of the biopharmaceutical company’s stock valued at $49,322,000 after purchasing an additional 48,751 shares during the last quarter. United Services Automobile Association bought a new position in shares of Incyte in the first quarter valued at about $219,000. Finally, Focus Partners Wealth lifted its stake in shares of Incyte by 74.1% during the 1st quarter. Focus Partners Wealth now owns 21,024 shares of the biopharmaceutical company’s stock worth $1,273,000 after buying an additional 8,951 shares during the last quarter. 96.97% of the stock is owned by institutional investors and hedge funds.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q4 results & guidance: Incyte reported Q4 revenue above expectations and outlined 10–13% revenue growth for 2026, citing pipeline expansion and new product launches — a clear near-term growth signal that investors rewarded. Incyte outlines 10–13% revenue growth for 2026
• Positive Sentiment: Analyst tone: Coverage pieces and aggregate analyst commentary remain constructive—Wall Street highlights steady growth and the pipeline, helping underpin sentiment despite the EPS miss. Do Wall Street Analysts Like Incyte Corporation Stock?
• Positive Sentiment: Asset monetization: Incyte sold the Wilmington Bracebridge towers to BPG, a real-estate disposition that should free cash / simplify the corporate footprint — modestly positive for cash flow and capital allocation. Incyte’s big downtown Wilmington move…
• Neutral Sentiment: Market commentary: Several pieces ask whether INCY’s ~43% one‑year run makes it “too late” to buy; these are opinion/valuation discussions that influence positioning but don’t change fundamentals immediately. Is It Too Late To Consider Incyte After Its 43% One Year Rally
• Neutral Sentiment: Media flow: Earnings-call highlights and coverage (transcripts, midday movers) are being digested; they offer color but largely reiterate the same beats/risks. Incyte Q4 Earnings Call Highlights
• Neutral Sentiment: Short-interest data appears inconsistent/erroneous in recent filings (reports show zero shares / NaN changes), so short-interest signals aren’t informative right now.
• Negative Sentiment: Opzelura guidance & Jakafi patent fears: A weaker 2026 revenue forecast for Opzelura raised renewed concerns about franchise vulnerability and potential spillover to Jakafi patent litigation/renewed competitive risk. Opzelura weak 2026 forecast heightens Jakafi patent concerns
• Negative Sentiment: EPS miss & share reaction: INCY missed on EPS for the quarter, which prompted a post‑earnings gap down in some sessions and is a key reason for caution despite the revenue beat. Shares Gap Down After Earnings Miss
• Negative Sentiment: Regulatory/pricing risk: Management flagged exposure to evolving U.S. drug‑pricing policies (e.g., Most Favored Nation‑style measures), which could pressure profitability if enacted. Profit Outlook Threatened by Pricing Policies

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.